Browse MED23

Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF11573 Mediator complex subunit 23
Function

Required for transcriptional activation subsequent to the assembly of the pre-initiation complex (By similarity). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors. Required for transcriptional activation by adenovirus E1A protein. Required for ELK1-dependent transcriptional activation in response to activated Ras signaling.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
Molecular Function GO:0003713 transcription coactivator activity
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MED23 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MED23 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.77; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MED23 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2220.376
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4450.727
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0620.946
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0540.854
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0320.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.160.949
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2230.537
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2710.861
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2090.901
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1880.85
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2170.365
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0610.216
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MED23 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MED23. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MED23. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MED23.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MED23. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MED23 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MED23 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMED23
Namemediator complex subunit 23
Aliases CRSP130; DRIP130; CRSP3; cofactor required for Sp1 transcriptional activation, subunit 3, 130kDa; ARC130; CR ......
Chromosomal Location6q22.33-q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MED23 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.